These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11514139)

  • 1. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).
    Heerding DA; Chan G; DeWolf WE; Fosberry AP; Janson CA; Jaworski DD; McManus E; Miller WH; Moore TD; Payne DJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Smith W; Takata DT; Vaidya KS; Yuan CC; Huffman WF
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2061-5. PubMed ID: 11514139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.
    Seefeld MA; Miller WH; Newlander KA; Burgess WJ; Payne DJ; Rittenhouse SF; Moore TD; DeWolf WE; Keller PM; Qiu X; Janson CA; Vaidya K; Fosberry AP; Smyth MG; Jaworski DD; Slater-Radosti C; Huffman WF
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2241-4. PubMed ID: 11527706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.
    Bergler H; Fuchsbichler S; Högenauer G; Turnowsky F
    Eur J Biochem; 1996 Dec; 242(3):689-94. PubMed ID: 9022698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
    Miller WH; Seefeld MA; Newlander KA; Uzinskas IN; Burgess WJ; Heerding DA; Yuan CC; Head MS; Payne DJ; Rittenhouse SF; Moore TD; Pearson SC; Berry V; DeWolf WE; Keller PM; Polizzi BJ; Qiu X; Janson CA; Huffman WF
    J Med Chem; 2002 Jul; 45(15):3246-56. PubMed ID: 12109908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.
    Kitagawa H; Ozawa T; Takahata S; Iida M; Saito J; Yamada M
    J Med Chem; 2007 Sep; 50(19):4710-20. PubMed ID: 17713898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus.
    Takahata S; Iida M; Yoshida T; Kumura K; Kitagawa H; Hoshiko S
    J Antibiot (Tokyo); 2007 Feb; 60(2):123-8. PubMed ID: 17420562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
    Seefeld MA; Miller WH; Newlander KA; Burgess WJ; DeWolf WE; Elkins PA; Head MS; Jakas DR; Janson CA; Keller PM; Manley PJ; Moore TD; Payne DJ; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Uzinskas IN; Wallis NG; Huffman WF
    J Med Chem; 2003 Apr; 46(9):1627-35. PubMed ID: 12699381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK.
    Ozawa T; Kitagawa H; Yamamoto Y; Takahata S; Iida M; Osaki Y; Yamada K
    Bioorg Med Chem; 2007 Dec; 15(23):7325-36. PubMed ID: 17892940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene.
    Heath RJ; Li J; Roland GE; Rock CO
    J Biol Chem; 2000 Feb; 275(7):4654-9. PubMed ID: 10671494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.
    Kim YG; Seo JH; Kwak JH; Shin KJ
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4481-6. PubMed ID: 26343826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel and potent class of FabI-directed antibacterial agents.
    Payne DJ; Miller WH; Berry V; Brosky J; Burgess WJ; Chen E; DeWolf WE; Fosberry AP; Greenwood R; Head MS; Heerding DA; Janson CA; Jaworski DD; Keller PM; Manley PJ; Moore TD; Newlander KA; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Salyers KL; Seefeld MA; Smyth MG; Takata DT; Uzinskas IN; Vaidya K; Wallis NG; Winram SB; Yuan CC; Huffman WF
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3118-24. PubMed ID: 12234833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI).
    Mehboob S; Song J; Hevener KE; Su PC; Boci T; Brubaker L; Truong L; Mistry T; Deng J; Cook JL; Santarsiero BD; Ghosh AK; Johnson ME
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1292-6. PubMed ID: 25677657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.
    Schiebel J; Chang A; Shah S; Lu Y; Liu L; Pan P; Hirschbeck MW; Tareilus M; Eltschkner S; Yu W; Cummings JE; Knudson SE; Bommineni GR; Walker SG; Slayden RA; Sotriffer CA; Tonge PJ; Kisker C
    J Biol Chem; 2014 Jun; 289(23):15987-6005. PubMed ID: 24739388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors.
    Rana P; Ghouse SM; Akunuri R; Madhavi YV; Chopra S; Nanduri S
    Eur J Med Chem; 2020 Dec; 208():112757. PubMed ID: 32883635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
    Yogiara ; Mordukhova EA; Kim D; Kim WG; Hwang JK; Pan JG
    Bioorg Med Chem Lett; 2020 Dec; 30(24):127651. PubMed ID: 33130290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action.
    Zheng CJ; Sohn MJ; Lee S; Kim WG
    PLoS One; 2013; 8(11):e78922. PubMed ID: 24312171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure-activity relationship analyses.
    Kronenberger T; Asse LR; Wrenger C; Trossini GH; Honorio KM; Maltarollo VG
    Future Med Chem; 2017 Feb; 9(2):135-151. PubMed ID: 28128024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel series of enoyl reductase inhibitors targeting the ESKAPE pathogens, Staphylococcus aureus and Acinetobacter baumannii.
    Kwon J; Mistry T; Ren J; Johnson ME; Mehboob S
    Bioorg Med Chem; 2018 Jan; 26(1):65-76. PubMed ID: 29162308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virtual screening of antibacterial compounds by similarity search of Enoyl-ACP reductase (FabI) inhibitors.
    Asse Junior LR; Kronenberger T; Magalhães Serafim MS; Sousa YV; Franco ID; Valli M; Silva Bolzani VD; Monteiro GC; Bruno Prates JL; Kroon EG; Fernandes Mota BE; Santos Ferreira DD; de Oliveira RB; Maltarollo VG
    Future Med Chem; 2020 Jan; 12(1):51-68. PubMed ID: 31729258
    [No Abstract]   [Full Text] [Related]  

  • 20. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli.
    Heath RJ; Rock CO
    J Biol Chem; 1995 Nov; 270(44):26538-42. PubMed ID: 7592873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.